Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for treating locally advanced or metastatic colorectal cancer
Following on from information provided to NICE by the company in May 2018 the appraisal of Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1298
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2018 the appraisal of Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 July 2018 | Note added to the project documents |
| 01 June 2018 | Suspended. Suspended |
| 26 April 2018 - 25 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 17 May 2018 | Note added to the project documents |
| 11 August 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual